CatalYm has initiated patient enrollment in the GDFATHER-HCC-01 trial, a Phase 2b study investigating visugromab as part of a combinatorial treatment strategy for patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have progressed following first-line anti-PD-(L)1 immunotherapy. According to PharmaTimes Online, the first patient has been successfully dosed, marking an important expansion of the therapeutic candidate into a critical clinical indication.
Trial Design and Treatment Approach
The global trial employs a two-stage design beginning with an open-label safety run-in phase to establish the recommended dose for the subsequent expansion phase. Following this confirmation step, the study transitions to a randomized, double-blind comparison evaluating visugromab in combination with nivolumab, a checkpoint inhibitor, and lenvatinib, a tyrosine kinase inhibitor standard of care for HCC. This triple-combination approach is contrasted against a control regimen of double placebo plus lenvatinib.
Mechanism and Rationale
Visugromab functions as a neutralizing antibody targeting GDF-15, an immunosuppressive cytokine secreted by tumor cells to circumvent immune surveillance. By blocking this immunosuppressive pathway, visugromab aims to restore immune system sensitivity and enhance the efficacy of concurrent immunotherapies. This mechanism appears particularly promising in HCC, where long-term survival outcomes remain suboptimal, and treatment options for post-immunotherapy progression are severely limited.
Clinical Evidence Foundation
Earlier exploratory findings from the Phase 1/2a GDFATHER trial demonstrated encouraging anti-tumor activity when visugromab was combined with anti-PD-1 antibody therapy, providing strong preclinical and early clinical rationale for the current Phase 2b investigation.
Study Parameters
The trial will enroll approximately 104 participants across 40 clinical sites spanning North America, Europe, and the Asia-Pacific region. The primary efficacy endpoint is progression-free survival, with secondary measures including overall survival, objective response rate, and assessment of visugromab’s potential to ameliorate cancer cachexia—a debilitating complication of advanced malignancy.
This expansion represents a strategic advancement in visugromab’s development pipeline, addressing hepatocellular carcinoma, the third leading cause of cancer-related mortality globally. By integrating an immune-restoring agent with established standards of care, CatalYm aims to establish a novel treatment paradigm capable of meaningfully improving clinical outcomes for patients with limited therapeutic alternatives.
